scispace - formally typeset
V

Vincent C. O. Njar

Researcher at University of Maryland, Baltimore

Publications -  154
Citations -  10648

Vincent C. O. Njar is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Prostate cancer & Androgen receptor. The author has an hindex of 42, co-authored 146 publications receiving 9790 citations. Previous affiliations of Vincent C. O. Njar include Saarland University & University of Maryland Marlene and Stewart Greenebaum Cancer Center.

Papers
More filters
Journal ArticleDOI

Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.

Adam Schayowitz, +3 more
- 01 Jan 2008 - 
TL;DR: It is suggested that compensatory cross-talk between the androgen receptor and various signaling pathways may account for decreased sensitivity to androgens receptor antagonists and the progression to hormone-resistant prostate cancer.
Journal ArticleDOI

Improved Synthesis of Histone Deacetylase Inhibitors (HDIs) (MS-275 and CI-994) and Inhibitory Effects of HDIs Alone or in Combination with RAMBAs or Retinoids on Growth of Human LNCaP Prostate Cancer Cells and Tumor Xenografts

Lalji K. Gediya, +5 more
- 15 Mar 2008 - 
TL;DR: The results demonstrate that compound 2 and its combination with SAHA are potentially useful agents that warrant further preclinical development for treatment of prostate cancer.
Journal ArticleDOI

Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors.

Vânia M. Moreira, +3 more
- 01 Dec 2007 - 
TL;DR: A series of novel 1H- and 2H-indazole derivatives of the commercially available dehydroepiandrosterone acetate have been synthesized and tested for inhibition of human cytochrome 17alpha-hydroxylase-C(17,20)-lyase (CYP17), androgen receptor (AR) binding affinity, and cytotoxic potential against three prostate cancer cell lines.
Journal ArticleDOI

Effects of new 17α-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo

Dmitry N. Grigoryev, +5 more
- 01 Oct 1999 - 
TL;DR: Two new inhibitors of a key regulatory enzyme of testicular and adrenal androgen synthesis 17α-hydroxylase/C17,20-lyase (P450c17) are suggested to be potential candidates for treatment of prostate cancer.
Journal ArticleDOI

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Daniel J. Klionsky, +2522 more
- 01 Jan 2016 - 
TL;DR: Author(s): Klionsky, DJ; Abdelmohsen, K; Abe, A; Abedin, MJ; Abeliovich, H; A Frozena, AA; Adachi, H, Adeli, K, Adhihetty, PJ; Adler, SG; Agam, G; Agarwal, R; Aghi, MK; Agnello, M; Agostinis, P; Aguilar, PV; Aguirre-Ghis